digital-therapeutics
(10)Shayan Khorassani
Shayan Khorassani is the Field CEO at Huma, the London-based AI health infrastructure company powering regulated digital health applications for pharma, providers, and governments across 70+ countries. A licensed architect turned health technology operator, he moved from designing physical structures at Tom Wiscombe Architecture and SCI-Arc to translating Huma's platform into deployments for global health systems.
Yusuf Sherwani
Yusuf Sherwani is a London-born, New York-based medical doctor turned founder who runs Pelago (formerly Quit Genius), the digital clinic he co-founded in 2017 with two medical school classmates, Maroof Ahmed and Sarim Siddiqui. A Y Combinator alumnus and Forbes 30 Under 30 honoree, he has raised more than $150 million from investors including Atomico, Kinnevik and Octopus Ventures to scale technology-driven, evidence-based care. Trained at Imperial College London with an MD and a BSc in management, he co-authored roughly a dozen peer-reviewed studies before pivoting fully into building. He is also an active angel investor backing early-stage founders and writes about healthcare, technology and finance on his personal blog.
Bozidar Jovicevic
Bozidar Jovicevic is the CEO and co-founder of Evermed, a New York startup that lets medical societies and healthcare organizations launch a Netflix-style, on-demand video library in about 90 days. A medical doctor and FIDE chess master who spent 17 years running global digital initiatives at Novartis and Sanofi, he now builds technology that turns conference recordings and expert lectures into searchable, monetizable continuing-education libraries for physicians. He also hosts the Pharma Launch Secrets and Digital Innovators Circle podcasts.
Raj Amin
Raj Amin is the co-founder and CEO of Arcade Therapeutics, a New York science-first game studio building prescription digital therapeutics that embed clinically proven anxiety-reduction techniques inside mobile games. A University of Pennsylvania-trained engineer and Wharton MBA, he has spent more than two decades building venture-backed companies at the seam of healthcare, media and technology - including HealthiNation, the first on-demand consumer health video network, and Mana Health, a health-data interoperability platform later acquired by Comcast. He is a self-described #GirlDad, a drummer and aspiring guitarist, and a Broadway investor who has backed Tony Award-winning productions.
Veera Anantha
Veera Anantha is the co-founder and CEO of Constant Therapy Health, a Boston-based digital therapeutics company whose AI-powered app helps people living with stroke, traumatic brain injury, aphasia and other neurological conditions rebuild speech, language and cognitive skills. A trained engineer and physicist with a PhD from Northwestern and a degree from IIT Bombay, he spent years building products at startups acquired by Apple and Motorola before turning to brain rehabilitation. Under his leadership the platform has delivered well over 100 million therapy exercises, creating what is described as the largest real-world brain rehabilitation dataset, and he champions AI that is accountable and explainable enough for healthcare.
Joel Morse
Joel Morse is the co-founder and CEO of Curavit Clinical Research, a virtual contract research organization (VCRO) that designs and runs decentralized clinical trials for digital therapeutics, devices and drugs. A mechanical engineer turned serial healthcare operator, he previously co-founded C3i Solutions in 1993 and built it into a global leader in tech-enabled clinical trial services before selling to Telerx in 2014. At Curavit he is betting that trials can be run where patients actually live, stitching together wearables, web recruitment and real-world evidence to reach people traditional sites never see.
Scott Xiao
Scott Xiao is the co-founder and CEO of Luminopia, a Boston-area digital therapeutics company whose lead product turns watching cartoons in a VR headset into an FDA-approved treatment for amblyopia, the leading cause of vision loss in children. He left Harvard with classmate Dean Travers to build the first VR-based therapeutic ever cleared by the FDA, partnering with Sesame Workshop, Nickelodeon, and DreamWorks for content and with Boston Children's Hospital and MIT for the science.
Maayan Cohen
Maayan Cohen is the Co-Founder and CEO of Hello Heart, a Menlo Park-based digital therapeutics company focused exclusively on cardiovascular health. A former Israeli tank platoon commander turned strategy consultant, she built Hello Heart from a 2013 startup into a platform covering 1.6+ million members across Fortune 500 employers, backed by $148.5M in funding from investors including Khosla Ventures, IVP, and Stripes. Named to CNBC Changemakers 2024 and Inc. Female Founders 500 in 2025, Cohen is recognized for her empathy-driven leadership style - including managing her company from Tel Aviv bomb shelters during the 2023 Israel-Hamas war while providing housing and support for both Israeli and Palestinian staff.
Mike Rosenbluth
Mike Rosenbluth is the Founder and CEO of Swing Therapeutics, the San Francisco-based company behind Stanza - the first FDA-authorized prescription digital therapeutic for fibromyalgia symptoms. A Stanford-trained mechanical engineer with a UC Berkeley PhD in Bioengineering, Rosenbluth spent years at McKinsey, a VC firm (Versant Ventures), and cancer diagnostics company Veracyte before founding Swing in 2019. His company's landmark PROSPER-FM Phase 3 trial results were published in The Lancet in 2024, and Swing has raised over $30 million to bring evidence-based, non-drug behavioral therapy to the estimated 4 million Americans with fibromyalgia.
Bob Schafer
Bob Schafer, PhD, is the CEO of Lumos Labs, the company behind Lumosity, the world's largest brain training platform with over 100 million users. A Stanford-trained neuroscientist with postdoctoral work at MIT, Schafer founded Prophecy Sciences (YC W13) before joining Lumos Labs via acquihire in 2015. He rose from Head of Research to Chief Science Officer to President of Lumosity DTx before being named CEO in May 2023. Under his leadership, Lumos Labs achieved FDA 510(k) clearance in December 2025 for LumosityRx (marketed as Prismira), the first prescription digital therapeutic for attention improvement in adults with ADHD — validated by a 500-participant randomized controlled trial.